Medtronic Announces FDA Approval Of Minimally Invasive Device To Treat Hypertension
Portfolio Pulse from Benzinga Newsdesk
Medtronic plc (NYSE:MDT) has received FDA approval for its Symplicity Spyral renal denervation system, a minimally invasive device to treat hypertension. The device, which delivers radiofrequency energy to nerves near the kidneys, represents a significant milestone in hypertension treatment. Medtronic will immediately begin commercialization in the U.S., addressing a major global health issue with a new treatment option that complements existing medications and lifestyle changes. The approval follows ten years of clinical research and development, and the device is already approved for commercial use in over 70 countries.
November 19, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medtronic's FDA approval for the Symplicity Spyral system is likely to boost investor confidence and potentially increase revenue as the company begins U.S. commercialization of this innovative hypertension treatment.
The FDA approval of a new medical device typically leads to increased investor confidence and can have a positive impact on a company's stock price in the short term. Given the prevalence of hypertension and the need for additional treatment options, this approval could lead to significant revenue growth for Medtronic. The company's immediate move to commercialize the product in the U.S. suggests a strong market opportunity and potential sales growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100